47.3 F
New York
Monday, March 1, 2021

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Must read

ChargePoint Inc [NYSE: CHPT] Announces The Completion Of Business Combination With SwithBack Energy

ChargePoint Inc revealed that the company has completed its business merger with Switchback Energy Acquisition Corp. Additionally, The companies uncover the close of...

Bank of America [NYSE: BAC] Announced Paid Break For Employees For Covid Vaccination

Bank Of America Corp  announced that the company will give its staff paid time off for covid vaccination. Moreover, the company states that...

Fidelity D and D Bancorp [NASDAQ: FDBC] Executes Acquisition Of Landmark Bancorp

Fidelity D and D Bancorp, Inc. announced the acquisition of Landmark Bancorp, Inc. The company reported executing the contract in which Landmark will...

Atlassian Corp [NYSE: TEAM] Announces The Acquisition Of Chartio

Atlassian Corporation announced the acquisition of Chartio. The acquisition of Chartio to the Atlassian stage will give a robust analytic experience across our...

Humanigen Inc [NASDAQ: HGEN] revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is the phase 3 treatment option for Covid19 which is currently in development.

Ajinomoto will provide drug product aseptic fill-finish service to Humanigen at its San Diego facility. By doing so the company will simplify the supply chain efforts for Humanigen to support continuing clinical trials efforts. Meanwhile, Humangien is keenly registering patients in the United States and Brazil for a phase 3 study. Moreover, the company is preparing applications for Covid 19 EUA for Lenzilumab.

Cameron Durrant CEO of Humanigen said “ We are glad to join forces with Ajinomoto BioPharma to support the fil finish of Lenzilumab. Moreover, The collaboration will enable us to use Ajinomoto’s drug product aseptic fill-finish facility to provide the timely supply of Lenzilumab.  We are nearly at end of the clinical study of phase 3 and ready for Emergency Use Authorization applications.”

More articles

Latest article

MongoDB [NASDAQ: MDB] Announces Extended 5-year Collaboration With Google Cloud

MongoDB Inc. , reported an extended five-year collaboration that will stretch out their current go-to-market relationship. Moreover, it will provide a more profound integration...

Humana Inc [NYSE: HUM] Announces Collaboration With Mercy

Mercy and  Humana Inc. announces that the companies have collaborated. Both the companies inked a contract to extend patient access to virtual healthcare...

International Paper [NYSE: IP] Reports Purchase Of Berkley MF LLC

International Paper has purchased Berkley International's Molded Fiber (Pulp) production subsidiary, Berkley MF LLC. Berkley is the provider of essential packaging and e-commerce...

Perspecta [NYSE: PRSP] Received an Award For $38 Million To Continue Supporting DMDC

Perspecta Inc. , reported that the company has been granted an award to keep supporting the Defense Manpower Data Center (DMDC) with a strategic...

SG Blocks [NASDAQ: SGBX] Continues Growth Through The Execution Of 19-acre Acquisition Contract

SG Blocks, Inc. executes the contract to purchase the 19 acre Echo sites and all of its multiple structures. The company reported the...

HP Inc [NYSE: HPQ] Enters Into A Contract To Purchase HyperX

HP Inc. revealed that the company entered into a contract to purchase HyperX. It is the gaming subsidiary of Kingston Technology Company. Moreover,...

AT&T [NYSE: T] Might Sell Its Large Minority Stake At Direct TV/ U-Verse Operation To TPG

AT&T is approaching a deal to sell a significant minority stake in its DirecTV, AT&T TV Now, and U-Verse business to TPG. Additionally,...

Wipro [NYSE: WIT] Entered Into A Collaborative Agreement With Uptake

Uptake revealed that the company has collaborated with Wipro limited . The companies inked the agreement to deliver industrial intelligence for the utilities, chemical...